Sgn35-031 A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study Of Brentuximab Vedotin Or Placebo In Combination With Lenalidomide And Rituximab In Subjects With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Posted Date: May 24, 2021
- Investigator: Tahir Latif
- Specialties: Cancer, Lymphoma, Oncology
- Type of Study: Drug
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The primary objective of this study is to study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Efficacy will be determined by measuring PFS per blinded independent central review (BICR) in the ITT population and PFS per BICR in the CD30-positive population.
Criteria:
Participants With Relapsed Or Refractory Diffuse And Transformed Large B-Cell Lymphoma (R/R Dlbcl), Participants Must Have R/R Disease Following 2 Or More Lines Of Prior Systemic Therapy, Participants Will Need To Have A Formalin-Fixed Paraffin-Embedded T
Keywords:
Lymphoma
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com